Survival and Survival ROC curves for the Risk Score. (a)

<p>Kaplan-Meier outcome-free survival curves by risk score tertiles; <b>(b)</b> the Risk Score’s ROC curves for predicting ESRD at 24 months, 60 months and 120 months.</p

Multivariate Cox Regression with Stepwise Selection (n = 619).

<p>SBP: systolic blood pressure.</p>*<p>Renal outcome defined as end-stage renal disease (ESRD).</p>**<p>Renal outcome defined as 50% decline from baseline eGFR.</p><p># The risk score was calculated from the coefficients of independent risk factors in model 1.</p

Univariate analysis of baseline variables with renal end points for ESRD.

<p>SBP: systolic blood pressure;</p><p>DBP: diastolic blood pressure;</p><p>MAP: mean arterial pressure;</p><p>UA: uric acid;</p><p>WBC: white blood cell count.</p><p># p<0.05.</p

Performance of the Published ESRD Prediction Scores.

<p>The ROC curves for predicting renal outcomes within (a) 24 months, (b) 60 months, and (c) 120 months of follow-up. The Risk Score from this study (black) is contrasted against the Goto et al. score (blue), RENAAL score (red) and the Berthoux et al. score (green); (d) comparisons of AUCs (and their 95% CIs) and R² for the four risk score prediction models.</p

Detailed Analysis of Hemoglobin and Serum Albumin Levels. (a)

<p>the distributions of hemoglobin levels for IgAN patients and healthy controls; <b>(b)</b> hemoglobin levels by the degree of renal impairment; <b>(c)</b> serum albumin distributions in IgAN patients and healthy controls; <b>(d)</b> serum albumin levels by the degree of renal impairment; <b>(e)</b> correlation between serum albumin and urine protein excretion by three different groups of proteinuria. Significance code: * p<0.05, ** p<0.01, *** p<0.001.</p

Kaplan-Meier Outcome-free Survival Curves.

<p><b>(a)</b> low (red) versus high (black) baseline eGFR group; <b>(b)</b> patients with a baseline diagnosis of anemia (red) versus no anemia (black); <b>(c)</b> patients with hypoalbuminemia (red) versus normoalbuminemia (black); <b>(d)</b> patients with systolic hypertension (red) versus normotensives (black). Censor points are denoted by vertical tick lines.</p

siRNA knock-down of C1GALT1, COSMC and COSMC+C1GALT1 in IgA1-secreting cell lines increases Gd-IgA1 production.

<p><b>(a)</b> knock-down in IgA1-secreting cell lines from healthy controls; mock-control (n = 5), non-targeting siRNA (n = 7), C1GALT1 siRNA (n = 5), COSMC siRNA (n = 7), and COSMC+C1GALT1 siRNA (n = 2); <b>(b)</b> knock-down in IgA1-secreting cell lines from IgAN patients; mock-control (n = 5), non-targeting siRNA (n = 7), C1GALT1 (n = 5), COSMC siRNA (n = 7), and COSMC+C1GALT1 siRNA (n = 2); <b>(c)</b> relative change in mRNA in IgA1-secreting cell lines after siRNA knock-down of C1GALT1 (n = 5), COSMC (n = 7), and COSMC+C1GALT1 (n = 2) compared to non-targeting siRNA control.</p

Combined results for new significant and suggestive GWAS signals: serum Gd-IgA1 levels were determined using HAA lectin-based ELISA, normalized and adjusted for age, case-control status and serum total IgA levels.

<p>Combined results for new significant and suggestive GWAS signals: serum Gd-IgA1 levels were determined using HAA lectin-based ELISA, normalized and adjusted for age, case-control status and serum total IgA levels.</p

Genotypic effects and worldwide allelic frequency distribution for the two top genome-wide significant loci.

<p><b>(a)</b> Mean trait values (+/- standard errors) by rs13226913 genotype at the <i>C1GALT1</i> locus. (<b>b</b>) The distribution of rs13226913 alleles across the Human Genome Diversity Panel (HGDP) populations. <b>(c)</b> Mean trait values (+/- standard errors) by rs5910940 genotype at the <i>C1GALT1C1</i> locus. <b>(d)</b> The distribution of rs5910940 alleles across HGDP populations. The allelic distribution plots were modified from the HGDP Selection Browser. The trait values were expressed as standard normal residuals of log-transformed serum Gd-IgA1 levels after adjustment for age, serum total IgA levels, case-control status and cohort membership.</p

Study cohorts after implementation of all quality control filters: the final counts of cases and controls by cohort are provided.

<p>Study cohorts after implementation of all quality control filters: the final counts of cases and controls by cohort are provided.</p